论文部分内容阅读
目的观察莫沙比利联合舒神灵胶囊治疗功能性消化不良(functional dyspesia,FD)的疗效。方法选择2009年1月—2012年6月收治的FD患者147例,随机分为治疗组50例、对照1组49例和对照2组48例。治疗组给予莫沙比利5 mg,3次/d,舒神灵胶囊20 mg,1次/d治疗;对照1组给予莫沙比利5 mg,3次/d;对照2组给予舒神灵胶囊20 mg,1次/d。治疗4周后比较三组的症状改善情况及胃动素(motilin,MTL)和促胃液素(gastrin,GAS)的变化。结果总有效率治疗组94.00%,治疗1组77.55%,治疗2组79.17%,治疗组与对照1组、对照2组比较差异均有统计学意义(均P<0.05)。治疗组血浆MTL和GAS与对照1组、对照2组比较,差异均有统计学意义(均P<0.05),且三组患者腹胀、腹痛、反胃、恶心、食欲不振等症状较治疗前均有明显改善。结论莫沙比利联合舒神灵胶囊治疗FD疗效明确,值得临床推广使用。
Objective To observe the therapeutic effect of mosapride and shushenling capsule on functional dyspesia (FD). Methods A total of 147 FD patients admitted from January 2009 to June 2012 were randomly divided into treatment group (n = 50), control group (n = 49) and control group (n = 48). The treatment group was given mosapride 5 mg, 3 times / d, Shushenling Capsule 20 mg once a day, the control group 1 was given mosapride 5 mg three times a day, the control group 2 Shushenling capsule 20 mg, 1 time / d. After 4 weeks of treatment, the improvement of symptoms and the changes of motilin (MTL) and gastrin (GAS) in the three groups were compared. Results The total effective rate was 94.00% in treatment group, 77.55% in treatment group 1 and 79.17% in treatment group 2, and there were significant differences between treatment group and control group 1 and control group 2 (all P <0.05). The plasma MTL and GAS in the treatment group were significantly different from those in the control group 1 and the control group 2 (all P <0.05), and the symptoms of abdominal distension, abdominal pain, nausea, nausea and loss of appetite in the three groups were statistically significant Significant improvement. Conclusion Mosapride joint Shushenling FD treatment of clear effect, it is worth promoting the use of the clinic.